Favipiravir
- CAS:259793-96-9
- Formula:C5H4FN3O2
- MW:157.1 Da
- Appearance:Off-white powder
- Purity:>99% by HPLC


Description
Favipiravir is an inhibitor of influenza viruses A, B, and C (IC50s: A = 0.03- 0.20 µg/mL H1N1; 0.01-0.30 H2N2; 0.08-0.48 H3N2; 0.14-0.15 H4N2; 0.24-1.60 H7N2; 0.20-0.82 H5N1; 0.35 H1N2; B = 0.04-0.09 µg/mL; C = 0.03-0.06 µg/mL) as well as strains resistant to adamantane-type antivirals, oseltamivir, and zanamivir1-3 . It displays no cytotoxicity in a variety of cell lines. Selectively inhibits viral RNA-dependent RNA polymerase4 . Displays activity against other viruses including arena, phlebo, hanta, flavi, entero, alpha, respiratory syncytial, and noroviruses5 . In clinical trials for treatment of SARS-CoV-26,7.
References
• "In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705"
• "Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates"
• "Mechanism of Action of T-705 against Influenza Virus"
• "Favipiravir (T-705), a novel viral RNA polymerase inhibitor"
• "Discovering drugs to treat coronavirus disease 2019 (COVID-19)"
• "A Review of SARS-CoV-2 and the Ongoing Clinical Trials"
Not for human therapeutic use or for medicinal purposes. For research applications only.
GHS PICTOGRAMS | ![]() |
---|---|
Handling | Avoid contact with skin and eyes. Ventilation and proper handling are to be used to prevent the formation of dusts and mists. Normal measures for preventative fire protection. No smoking, eating or drinking around this material. Wash hands after use. |